178 related articles for article (PubMed ID: 30507300)
41. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway.
Cao R; Meng Z; Liu T; Wang G; Qian G; Cao T; Guan X; Dan H; Xiao Y; Wang X
Oncotarget; 2016 Nov; 7(45):72941-72960. PubMed ID: 27662662
[TBL] [Abstract][Full Text] [Related]
42. Counting missing values in a metabolite-intensity data set for measuring the analytical performance of a metabolomics platform.
Huan T; Li L
Anal Chem; 2015 Jan; 87(2):1306-13. PubMed ID: 25496403
[TBL] [Abstract][Full Text] [Related]
43. Metabolomics for the diagnosis of bladder cancer: A systematic review.
García-Perdomo HA; Dávila-Raigoza AM; Korkes F
Asian J Urol; 2024 Apr; 11(2):221-241. PubMed ID: 38680576
[TBL] [Abstract][Full Text] [Related]
44. Gastric cancer: Metabolic and metabolomics perspectives (Review).
Xiao S; Zhou L
Int J Oncol; 2017 Jul; 51(1):5-17. PubMed ID: 28535006
[TBL] [Abstract][Full Text] [Related]
45. Metabolomic studies of breast cancer in murine models: A review.
Araújo R; Bispo D; Helguero LA; Gil AM
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165713. PubMed ID: 32014550
[TBL] [Abstract][Full Text] [Related]
46. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer.
Jobu K; Sun C; Yoshioka S; Yokota J; Onogawa M; Kawada C; Inoue K; Shuin T; Sendo T; Miyamura M
Biol Pharm Bull; 2012; 35(4):639-42. PubMed ID: 22466574
[TBL] [Abstract][Full Text] [Related]
47. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
48. Metabolomics and bladder cancer.
Hyndman ME; Mullins JK; Bivalacqua TJ
Urol Oncol; 2011; 29(5):558-61. PubMed ID: 21930087
[TBL] [Abstract][Full Text] [Related]
49. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
[TBL] [Abstract][Full Text] [Related]
50. High-throughput metabolomics for discovering metabolic biomarkers from intestinal tumorigenesis in APC
Guo XD; Liu L; Xiao HY
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():131-139. PubMed ID: 30316137
[TBL] [Abstract][Full Text] [Related]
51. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
52. Metabolomic Signatures of Treatment Response in Bladder Cancer.
Vieira de Sousa T; Guedes de Pinho P; Pinto J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139377
[TBL] [Abstract][Full Text] [Related]
53. Metabolomics and detection of colorectal cancer in humans: a systematic review.
Wang H; Tso VK; Slupsky CM; Fedorak RN
Future Oncol; 2010 Sep; 6(9):1395-406. PubMed ID: 20919825
[TBL] [Abstract][Full Text] [Related]
54. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer.
Zhou Y; Song R; Zhang Z; Lu X; Zeng Z; Hu C; Liu X; Li Y; Hou J; Sun Y; Xu C; Xu G
Anal Bioanal Chem; 2016 Sep; 408(24):6741-9. PubMed ID: 27473428
[TBL] [Abstract][Full Text] [Related]
55. Metabolomics of cancer.
Serkova NJ; Glunde K
Methods Mol Biol; 2009; 520():273-95. PubMed ID: 19381962
[TBL] [Abstract][Full Text] [Related]
56. A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Lee S; Ku JY; Kang BJ; Kim KH; Ha HK; Kim S
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564407
[TBL] [Abstract][Full Text] [Related]
57. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.
Zhang F; Zhang Y; Zhao W; Deng K; Wang Z; Yang C; Ma L; Openkova MS; Hou Y; Li K
Oncotarget; 2017 May; 8(21):35460-35472. PubMed ID: 28389626
[TBL] [Abstract][Full Text] [Related]
58. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
59. NMR-based metabolomic analysis of human bladder cancer.
Cao M; Zhao L; Chen H; Xue W; Lin D
Anal Sci; 2012; 28(5):451-6. PubMed ID: 22687923
[TBL] [Abstract][Full Text] [Related]
60. Serum metabolomics as a novel diagnostic approach for disease: a systematic review.
Zhang A; Sun H; Wang X
Anal Bioanal Chem; 2012 Sep; 404(4):1239-45. PubMed ID: 22648167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
